Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
3.28 EUR
329.69 M EUR
2.28 B EUR
97.68 M
About Neurocrine Biosciences, Inc.
Sector
CEO
Kyle W. Gano
Headquarters
San Diego
Website
Founded
1992
FIGI
BBG000KQ92B3
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where NB3 is featured.
Frequently Asked Questions
The current price of NB3 is 112.20 EUR — it has decreased by −2.86% in the past 24 hours. Watch NEUROCRINE BIOSCIENCES INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange NEUROCRINE BIOSCIENCES INC stocks are traded under the ticker NB3.
NB3 stock has fallen by −22.53% compared to the previous week, the month change is a −16.31% fall, over the last year NEUROCRINE BIOSCIENCES INC has showed a −8.18% decrease.
We've gathered analysts' opinions on NEUROCRINE BIOSCIENCES INC future price: according to them, NB3 price has a max estimate of 185.94 EUR and a min estimate of 133.65 EUR. Watch NB3 chart and read a more detailed NEUROCRINE BIOSCIENCES INC stock forecast: see what analysts think of NEUROCRINE BIOSCIENCES INC and suggest that you do with its stocks.
NB3 stock is 4.56% volatile and has beta coefficient of 0.53. Track NEUROCRINE BIOSCIENCES INC stock price on the chart and check out the list of the most volatile stocks — is NEUROCRINE BIOSCIENCES INC there?
Today NEUROCRINE BIOSCIENCES INC has the market capitalization of 12.05 B, it has decreased by −18.18% over the last week.
Yes, you can track NEUROCRINE BIOSCIENCES INC financials in yearly and quarterly reports right on TradingView.
NEUROCRINE BIOSCIENCES INC is going to release the next earnings report on Apr 30, 2025. Keep track of upcoming events with our Earnings Calendar.
NB3 earnings for the last quarter are 0.97 EUR per share, whereas the estimation was 1.55 EUR resulting in a −37.72% surprise. The estimated earnings for the next quarter are 0.84 EUR per share. See more details about NEUROCRINE BIOSCIENCES INC earnings.
NEUROCRINE BIOSCIENCES INC revenue for the last quarter amounts to 606.34 M EUR, despite the estimated figure of 608.04 M EUR. In the next quarter, revenue is expected to reach 594.92 M EUR.
NB3 net income for the last quarter is 99.59 M EUR, while the quarter before that showed 116.58 M EUR of net income which accounts for −14.57% change. Track more NEUROCRINE BIOSCIENCES INC financial stats to get the full picture.
No, NB3 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, NB3 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NEUROCRINE BIOSCIENCES INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NEUROCRINE BIOSCIENCES INC technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NEUROCRINE BIOSCIENCES INC stock shows the sell signal. See more of NEUROCRINE BIOSCIENCES INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.